Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Innate Pharma S.A.
Headquarters: Marseille, France
Website: http://www.innate-pharma.com...
Year Founded: 1999
Status: Public
Industry Sector: HealthTechnology
CEO: Jonathan Dickinson, MBA
Number Of Employees: N/A
Enterprise Value: $111,285,580
PE Ratio: -2.71
Exchange/Ticker 1: Euronext Paris:IPH
Exchange/Ticker 2: NASDAQ:IPHA
Latest Market Cap: $152,504,715
BioCentury | Dec 5, 2024
Discovery & Translation
Science Spotlight: Advances in RSV and hMVP vaccines
BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
BioCentury | Oct 15, 2024
Management Tracks
Jonathan Dickinson at the helm of Innate
Plus: Sernova hires CFO and updates from Inventiva
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Jun 6, 2024
Product Development
Solid tumor immunotherapies headline ASCO’s first-in-human studies
A focus on first-in-class innovation and solid tumor applications
BioCentury | Dec 19, 2023
Management Tracks
Xin Fu named CFO at InnoCare
Plus: Mahjoubi resigns as CEO of Innate, and updates from Viatris, Vicore,
BioCentury | Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Dec 20, 2022
Deals
Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal
Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more
BioCentury | Sep 27, 2022
Deals
Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor
The engineered CasX deal builds on the pharma’s 2020 Kiadis takeout
BioCentury | Aug 2, 2022
Finance
Aug. 1 Quick Takes: Qiming, Quan lead $120M series B for OriCell
Plus Concert preps JAK1/2 NDA and updates from Otonomy, Stealth and more
BioCentury | May 3, 2022
Deals
Gilead’s $300M deal with Dragonfly builds on 2022’s NK cell momentum
Dragonfly attracts Gilead as fourth big biopharma partner
Items per page:
1 - 10 of 179